2OAY image
Deposition Date 2006-12-18
Release Date 2007-05-01
Last Version Date 2024-10-16
Entry Detail
PDB ID:
2OAY
Title:
Crystal structure of latent human C1-inhibitor
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.35 Å
R-Value Free:
0.21
R-Value Work:
0.17
R-Value Observed:
0.17
Space Group:
P 65
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Plasma protease C1 inhibitor
Gene (Uniprot):SERPING1
Mutations:allele V458M
Chain IDs:A
Chain Length:390
Number of Molecules:1
Biological Source:Homo sapiens
Modified Residue
Compound ID Chain ID Parent Comp ID Details 2D Image
ASN A ASN GLYCOSYLATION SITE
Primary Citation
C1 inhibitor serpin domain structure reveals the likely mechanism of heparin potentiation and conformational disease
J.Biol.Chem. 282 21100 21109 (2007)
PMID: 17488724 DOI: 10.1074/jbc.M700841200

Abstact

C1 inhibitor, a member of the serpin family, is a major down-regulator of inflammatory processes in blood. Genetic deficiency of C1 inhibitor results in hereditary angioedema, a dominantly inheritable, potentially lethal disease. Here we report the first crystal structure of the serpin domain of human C1 inhibitor, representing a previously unreported latent form, which explains functional consequences of several naturally occurring mutations, two of which are discussed in detail. The presented structure displays a novel conformation with a seven-stranded beta-sheet A. The unique conformation of the C-terminal six residues suggests its potential role as a barrier in the active-latent transition. On the basis of surface charge pattern, heparin affinity measurements, and docking of a heparin disaccharide, a heparin binding site is proposed in the contact area of the serpin-proteinase encounter complex. We show how polyanions change the activity of the C1 inhibitor by a novel "sandwich" mechanism, explaining earlier reaction kinetic and mutagenesis studies. These results may help to improve therapeutic C1 inhibitor preparations used in the treatment of hereditary angioedema, organ transplant rejection, and heart attack.

Legend

Protein

Chemical

Disease

Primary Citation of related structures